Subcutaneous mosunetuzumab in R/R B-cell lymphoma

(1:20)

The value of mosunetuzumab in R/R FL

(1:46)

Mosunetuzumab in B-NHL R/R to CAR-T

(1:26)

Efficacy and safety of mosunetuzumab monotherapy for R/R follicular lymphoma

(1:12)

Mosunetuzumab in B-NHL R/R to CAR-T

(1:45)

Mosunetuzumab in untreated FL and MZL: a response-adapted trial

(55)

Mosunetuzumab: next-generation antibody for follicular lymphoma

(7:9)

Dr. Budde Highlights Unique Aspects of Mosunetuzumab Trial in Follicular Lymphoma

(53)

Pivotal findings from a Phase I/II trial of mosunetuzumab monotherapy for R/R follicular lymphoma

(5:25)

Mosunetuzumab in the treatment of HCL: a case study

(1:30)

Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients

(4:50)

SUNMO: mosunetuzumab + polatuzumab vedotin vs R-GemOx in R/R aggressive NHL

(49)

Epcoritamab versus mosunetuzumab in patients with R/R FL: findings of a MAIC

(2:16)

Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma

(3:47)

Mosunetuzumab induces CR in B-NHL R/R to CAR-T

(9:26)

Mosunetuzumab monotherapy in R/R FL

(2:4)

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R FL

(1:55)

Mosunetuzumab for chemotherapy-intolerant DLBCL

(2:52)

Mosunetuzumab individualized risk mitigation approach for NHL

(2:42)

Bispecific mosunetuzumab shows promise in R/R follicular lymphoma and DLBCL

(1:21)